Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus
Authors:
- Stanislava Stosic‐GrujicicSSStanislava Stosic‐Grujicic
- Ivana StojanovicISIvana Stojanovic
- Danijela Maksimovic‐IvanicDMDanijela Maksimovic‐Ivanic
- Miljana MomcilovicMMMiljana Momcilovic
- Dusan PopadicDPDusan Popadic
- Ljubica HarhajiLHLjubica Harhaji
- Djordje MiljkovicDMDjordje Miljkovic
- Christine MetzCMChristine Metz
- Katia ManganoKMKatia Mangano
- Gianpaolo PapaccioGianpaolo Papaccio
- Ferdinando NicolettiFerdinando Nicoletti
- 6 December 2007
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 215 (3) , 665-675
Abstract
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine of the innate immune system that plays a major role in the induction of immunoinflammatory responses. To examine the role of endogenous MIF in the pathogenesis of type 1 diabetes (TID) we evaluated the effects of administration of neutralizing anti‐MIF antibodies to NOD mice with accelerated forms of diabetes induced by injection of cyclophosphamide or by transfer of diabetogenic spleen cells. Both accelerated forms of diabetes were markedly reduced by anti‐MIF antibody. Furthermore, MIF‐deficient (MIF−/−) mice were less susceptible to the induction of immunoinflammatory diabetes, insulitis and apoptosis within the endocrine pancreas by multiple low doses of streptozotocin (MLD‐STZ) than genetically matched wild type (WT) mice. MIF deficiency resulted in lower proliferation and lymphocyte adhesion, as well as reduced production from the spleens and peritoneal cells of a variety of inflammatory mediators typically associated with development of the disease including IL‐12, IL‐23, TNF‐α, and IL‐1β. Furthermore, MIF deletion affected the production of IL‐18, TNF‐α, IL‐1β, and iNOS in the islets of Langerhans. These data, along with the higher expression of IL‐4 and TGF‐β observed in the periphery and in the pancreas of MLD‐STZ‐challenged MIF−/− mice as compared to WT controls suggest that MIF deficiency has induced an immune deviation towards protective type 2/3 response. These results suggest that MIF participates in T1D by controlling the functional activity of monocytes/macrophages and T cells and modulating their secretory capacity of pro‐ and anti‐inflammatory molecules. J. Cell. Physiol. 215: 665–675, 2008.Keywords
This publication has 74 references indexed in Scilit:
- Matrix Metalloproteinase-2 Dysregulation in Type 1 DiabetesDiabetes Care, 2007
- Mechanistic insights into targeting T cell membrane proteinase to promote islet β‐cell rejuvenation in type 1 diabetesThe FASEB Journal, 2006
- Lack of macrophage migration inhibitory factor protects mice against concanavalin A‐induced liver injuryLiver International, 2006
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaquesCardiovascular Research, 2005
- MACROPHAGE MIGRATION INHIBITORY FACTOR LEVELS CORRELATE WITH FATAL OUTCOME IN SEPSISShock, 2004
- Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: Incorporating disease outcome into the definition of phenotypeArthritis & Rheumatism, 2003
- Autoimmune versus inflammatory type I diabetes: a controversy?Immunology Today, 1995
- Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB ratsFEBS Letters, 1993
- Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in miceBiochemical and Biophysical Research Communications, 1991